This is to inform you that the Board of Directors of National Peroxide Limited at their meeting held today i.e., on April 30, 2026, had inter-alia considered and approved the following ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.6 pts more than Nifty Microcap 250 and 18.0 pts more than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
National Peroxide Limited reported FY2026 revenue of Rs 28,687.40 lakh, marginally down from Rs 28,971.14 lakh in FY2025 (approx 1% decline). However, PAT surged 39% to Rs 1,103.71 lakh from Rs 792.86 lakh, driven by cost optimizations. The Board recommended a final dividend of Rs 7 per share (70%). Statutory auditors Kalyaniwalla & Mistry LLP issued an Unmodified Opinion. The auditor drew an Emphasis of Matter on proposed commission of Rs 17 lakh to Non-Executive Directors requiring shareholder approval as it exceeds Section 197 limits. An exceptional item of Rs 58.15 lakh was recorded due to Social Security Code implementation costs. Key management change: Mr. Amit Goriwale stepped down as Interim CFO & CRO effective May 31, 2026, succeeded by Mr. Chirag Kothari (Chartered Accountant with 20+ years experience) effective June 1, 2026.
Positive PAT growth of 39% despite flat revenue indicates improved operational efficiency. Dividend payment and clean audit report are shareholder-friendly. The CFO transition appears planned and non-alarming. No going concern issues identified.